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Abstract
 
Genetic dissection of lupus pathogenesis in the NZM2410 strain has recently revealed that 
 
Sle1
 
is a potent locus that triggers the formation of IgG anti-histone/DNA antibodies, when ex-
pressed on the B6 background as a congenic interval. B6.
 
lpr
 
 mice, in contrast, exhibit distinctly
different cellular and serological phenotypes. Both strains, however, do not usually exhibit
pathogenic autoantibodies, or succumb to lupus nephritis. In this study, we show that the epi-
static interaction of 
 
Sle1
 
 (in particular, 
 
Sle1
 
/
 
Sle1
 
) with 
 
FAS
 
lpr
 
 leads to massive lymphospleno-
megaly (with elevated numbers of activated CD4 T cells, CD4
 
 
 
CD8
 
 
 
 double negative (DN) T
 
cells, and B1a cells), high levels of IgG and IgM antinuclear (including anti-ssDNA, anti-dsDNA,
and anti-histone/DNA), and antiglomerular autoantibodies, histological, and clinical evidence
of glomerulonephritis, and 
 
 
 
80% mortality by 5–6 mo of age. Whereas 
 
FAS
 
lpr
 
 functions as a
recessive gene, 
 
Sle1
 
 exhibits a gene dosage effect. These studies indicate that 
 
Sle1
 
 and 
 
FAS
 
lpr
 
must be impacting alternate pathways leading to lymphoproliferative autoimmunity.
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Introduction
 
Lupus is a truly polygenic disease where several distinct
genetic aberrations and pathogenic events collectively or-
chestrate antinuclear antibody (ANA)
 
*
 
 mediated systemic
 
end-organ damage (for a review, see references 1 and 2). In
 
particular, 
 
Sle1, Sle2
 
, and 
 
Sle3
 
 are three major lupus suscep-
tibility loci in the NZM2410 murine lupus model (3).
When introgressed onto the normal C57BL/6 (B6) back-
ground, the NZM2410 alleles of these loci lead to very
different immunophenotypes (4–13). 
 
Sle1
 
 triggers the for-
mation of anti-histone/DNA Abs that react poorly with
naked dsDNA (7). 
 
Sle2
 
 effects generalized B cell hyperac-
tivity, leading to an expansion of B1 cells, and increased se-
rum polyclonal/polyreactive Ig (6, 8). In contrast, 
 
Sle3
 
leads to reduced activation-induced T cell death (AICD),
increased CD4:CD8 ratios, and low-grade antinuclear se-
roreactivity (9). Although none of these loci engender se-
vere glomerulonephritis in isolation, the epistatic interac-
tion of these loci leads to high-titred anti-dsDNA ANAs,
severe GN, and mortality (10, 13).
The B6.
 
Sle1
 
 strain has a rather peculiar seroprofile, com-
pared with most other lupus-prone strains. In the BWF1
and MRL/
 
lpr
 
 lupus models, as well as in lupus patients,
anti-histone/DNA ANAs appear early in disease, and pre-
cede the emergence of anti-dsDNA ANAs (14–16). In
contrast, this transition to anti-dsDNA (and nephrophilic)
ANAs does not routinely occur in the B6.
 
Sle1
 
 strain.
Thus,
 
 
 
30% of these mice progress to develop anti-dsDNA
ANA (7). This phenotype is reminiscent of that seen in pa-
tients with drug-induced lupus, who also develop anti-his-
tone/DNA ANAs, but not renal disease (17). These obser-
vations suggest that anti-histone/DNA ANAs may not be
pathogenic. More interestingly, these studies lend credence
to the notion that anti-histone/DNA B cells may be regu-
lated differently from anti-dsDNA B cells. Although 
 
Sle1
 
may be sufficient to breach tolerance of anti-histone/DNA
B-cells, additional mechanisms may be in place to check
the emergence and evolution of anti-dsDNA B cells, and
any consequent pathology.
 
Since 
 
Sle3
 
 has the potential to augment anti-dsDNA
production, in epistasis with 
 
Sle1, Sle3
 
 may be representa-
tive of loci that regulate tolerance of anti-dsDNA B cells.
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toneal cavity. 
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Sle1
 
 and 
 
FAS
 
 Impact Alternate Pathways to Lymphoproliferative Lupus
 
Although the culprit gene(s) within the 
 
Sle3
 
 locus remains
unknown, we already know that 
 
Sle3
 
 has the potential to
impair AICD, leading to an accumulation of activated T
and B cells, with increasing age (9). Indeed, in many re-
spects these phenotypes parallel those seen in 
 
FAS
 
lpr/lpr
 
mice. The 
 
lpr
 
 mutation of 
 
FAS
 
 also impairs activation-
induced lymphocyte apoptosis, leading to an accumulation of
activated lymphocytes, serum anti-dsDNA ANAs, and clin-
ical autoimmunity on certain genetic backgrounds (18, 19).
Although loci such as 
 
Sle1
 
 may be critical in modulating
immune tolerance of anti-histone/DNA B cells, the regu-
lation of anti-dsDNA specificities (and hence the develop-
ment of end-organ disease) may require additional check-
points, such as those modulated by 
 
Sle3
 
 and 
 
FAS
 
. In this
study we test this hypothesis by generating B6.
 
Sle1|lpr
 
mice, bearing both 
 
Sle1
 
 and 
 
FAS
 
lpr/lpr
 
. Interestingly, these
mice have greatly elevated levels of nephrophilic, anti-
dsDNA ANAs, prominent lymphoadenopathy and spleno-
megaly, and accelerated mortality, compared with B6,
B6.
 
Sle1
 
, and B6.
 
lpr
 
 controls. These observations suggest
that the more pathogenic specificities (such as anti-dsDNA
and nephrophilic Abs) must have been effectively tolerized
in B6.
 
Sle1
 
 mice through 
 
FAS
 
/
 
FASL
 
-dependent mecha-
nisms. Thus, 
 
Sle1
 
 and 
 
FAS
 
 appear to be impacting two al-
ternate, nonredundant, pathways leading to lymphoprolif-
erative autoimmunity.
 
Materials and Methods
 
Mice.
 
C57BL/6 (B6) mice were obtained from The Jackson
Laboratory and subsequently bred in our animal colony. The
derivation of B6 congenic mice bearing NZM2410 derived lu-
pus-susceptibility intervals has been detailed previously (4).
B6.
 
Sle1
 
 (i.e., B6.
 
Sle1
 
NZM
 
/
 
NZM
 
) mice are C57BL/6 mice congenic
homozygotes for a 37 centimorgan interval on murine chromo-
some 1, spanning the 95% confidence interval flanking 
 
Sle1
 
, de-
rived from NZM2410, with termini at 
 
D1MIT101
 
 and
 
D1MIT155
 
. The immunological phenotypes of this strain have
been reported previously (7). B6 mice bearing homozygous
 
FAS
 
lpr/lpr
 
 mutations were obtained from The Jackson Laboratory,
and are referred to as B6.
 
lpr
 
, for simplicity (18). B6.
 
Sle1|lpr
 
 mice
expressing 
 
Sle1
 
 and 
 
FAS
 
lpr/lpr
 
, both homozygously, were derived
by breeding B6.
 
Sle1
 
 with B6.
 
lpr
 
 mice for two generations, and
then selecting F2 progeny that were homozygous at both loci. In
addition, where indicated, mice bearing single copies of these
loci were also studied. Thus, B6.
 
Sle1
 
 
 
/
 
 
 
|lpr
 
 mice are homo-
zygous for 
 
FAS
 
lpr
 
, but heterozygous at 
 
Sle1
 
. Likewise,
B6.
 
Sle1|lpr
 
 
 
/
 
 
 
 mice are homozygous at 
 
Sle1
 
, but heterozygous
for 
 
FAS
 
lpr
 
. The primers used to identify the 
 
Sle1
 
 interval and
 
FAS
 
lpr
 
 have been detailed previously (4, 7, 20). All mice used for
this study were bred and housed in a specific pathogen free col-
ony at UT Southwestern Medical Center Department of Animal
Resources in Dallas, TX. Equal numbers of male and female
mice were used for all experiments, and any observed sex differ-
ences are indicated.
 
Cell Preparation and Culture.
 
Splenocytes were depleted of
red blood cells using Tris Ammonium Chloride, and single-cell
suspensions were prepared for culture or flow cytometric analysis
(described below). LN cells were obtained from the inguinal
sites, and crushed to obtain single cell suspensions, for FACS
 
®
 
analysis. Peritoneal cavity (PerC) cells were obtained by flushing
the peritoneal cavities with fresh media. For the in vitro ANA
production assays, red cell–depleted splenocytes were cultured
(10
 
6
 
 cells per well) with or without LPS (20 ug/ml; Sigma-
Aldrich) at 37
 
 
 
C. Supernatants were harvested 5 d after culture,
diluted 1:2, and assayed for total IgG or IgG ANAs by ELISA, as
described below.
 
Flow Cytometric Analysis and Antibodies.
 
FACS
 
®
 
 was performed
as described previously (6–10). In brief, cells were first blocked
with staining medium (PBS, 5% horse serum, 0.05% azide) con-
taining 10% normal rabbit serum. Cells were then stained on
ice with optimal amounts of FITC, phycoerythrin, or biotin-
conjugated primary Abs diluted in staining medium for 30 min.
The following dye- or biotin-coupled Abs were obtained from
BD PharMingen: CD4 (RM4–5); CD5 (53–7.3); CD8 (Ly-2);
CD23 (B3B4); CD24 (M1/69); CD25 (7D4); CD43 (S7); CD44
(IM7); CD45R/B220 (RA3–6B2); CD62L (MEL14); CD69
(H1.2F3); CD80/B7–1 (16–10A1); CD86/B7–2 (GL1); and used
at pretitrated dilutions. After two washes, the biotin-conjugated
Abs were revealed using streptavidin-Tricolor (Caltag), or
streptavidin-Quantum Red (Sigma-Aldrich). Cell staining was
analyzed using a FACScan™ (Becton Dickinson). Dead cells
were excluded on the basis of scatter characteristics, and 10,000
events were acquired per sample. The mean linear units on
the forward scatter channel were used as indicators of cell size.
CD3
 
 
 
ve T cells that did not express CD4 or CD8, were classified
as double negative (DN) T cells. Cell sorting was conducted us-
ing a FACStar™ machine (Becton Dickinson). B1a (B220
 
int
 
,
CD23
 
lo
 
, CD5
 
 
 
ve) or B2 cells (B220
 
hi
 
, CD23
 
hi
 
, CD5-ve) were
sorted after staining for B220, CD23, and CD5. Sorted cells were
typically 
 
 
 
95% pure.
 
ELISA for Total Ig.
 
Total serum IgM and IgG levels were as-
sayed using a sandwich ELISA. In brief, goat anti–mouse IgM or
IgG (Boehringer Mannheim) was first coated onto Immulon I
plates and blocked. Sera was diluted serially and added to the
plates for 2 h at room temperature. Bound Ig was revealed with
alkaline-phosphatase conjugated goat anti–mouse IgM or IgG
Abs (Boehringer Mannheim), using pNPP as a substrate. Serial
dilutions of isotype-specific Ig standards were also added to each
plate, for quantitation and interplate standardization.
 
ELISA for Autoantibodies.
 
The anti-dsDNA, anti-histone, and
anti-histone/DNA ELISAs were performed as described previ-
ously (21). For the anti-dsDNA ELISA, Immulon II plates (Dy-
natech) precoated with methylated BSA (mBSA), were coated
overnight with 50 ug/ml dsDNA (Sigma-Aldrich, dissolved in
PBS, and filtered through cellulose acetate before use). For the
anti-histone/DNA ELISA, the dsDNA-coated plates were then
postcoated with 10 ug/ml of “total” histones (a mixture of all hi-
stones, purchased from Boehringer Mannheim) overnight at 4
 
 
 
C. Af-
ter blocking with PBS/3% BSA/0.1% gelatin/3 mM EDTA, 1:100
(starting) dilutions of the test-sera, or 1:2 dilutions of culture
supernatants, were incubated in duplicate for 2 h at room
temperature. Bound IgG was detected with alkaline phosphatase-
conjugated anti–mouse IgG (Jackson Immunoresearch Labora-
tory), using pNPP as a substrate. Raw optical density was con-
verted to U/ml, using a positive control mAb derived from an
NZM2410 mouse, arbitrarily setting the reactivity of a 1:100 di-
lution of this serum to 100 U/ml. This control mAb showed
equally strong (OD) reactivities to dsDNA and histone/DNA.
Sera with reactivities stronger than the test standard were diluted
further and reassayed. The glomerular-binding ELISA was per-
formed as described previously (10), using sonicated rat glomeruli
as substrate. 
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Histopathology.
 
Mice were killed at 3 or 6 mo of age (or ear-
lier, if evidently in distress), and kidneys, spleens, and other inter-
nal organs were fixed, sectioned, and stained with H&E, and pe-
riodic acid Schiff. For the analysis of kidney sections, at least 100
glomeruli were examined per section, by light microscopy, for
evidence of inflammation, and/or tissue damage, as described
previously (22), in a blinded fashion. In brief, the severity of GN
was graded on 0 to 4 scale, in which the grades 1, 2, 3, and 4,
were accorded when 1–10%, 11–25%, 26–50%, and 
 
 
 
50% of the
glomeruli were affected, respectively. GN of grades 3–4 is re-
ferred to in this communication as “severe GN.” The occurrence
of any mesangiopathic, capillary hyaline, proliferative, membra-
nous, or crescentic, glomerular changes was also noted. In addi-
tion, kidneys were also tested for evidence of Ig deposits by indi-
rect immunofluorescence. Spleens and nodes were examined for
their architecture, and any evidence of atypical hyperplasia, lym-
phomas, etc. In addition, the lungs, hearts, thymus, alimentary
tracts, salivary glands, pancreas, liver, and skin of these mice were
also sectioned, stained with H&E, and screened for any evidence
of pathology.
 
Clinical Nephritis.
 
Mice were monitored at 3 and 6 mo of age
for evidence of clinical nephritis. The total amount of urinary
protein was assayed using metabolic cages for urine collection,
and a Coomassie-based assay (Pierce Chemical Co.). Typically,
normal B6 mice do not excrete 
 
 
 
1 mg urinary protein per day.
In addition the levels of blood urea nitrogen (BUN) were mea-
sured using a commercially available kit (Sigma-Aldrich). Typi-
cally, normal B6 mice do not exhibit 
 
 
 
30 mg/dl BUN.
 
Statistics.
 
Where the samples studied were normally distrib-
uted, statistical comparisons were performed using the Students’ 
 
t
 
test. Where the samples deviated from normality, a nonparamet-
ric, Mann Whitney Rank-Sum test was used for comparisons.
Statistical analyses were performed using SigmaStat software. For
all experiments, the mean and the SEM are also depicted.
 
Results
B6.Sle1|lpr Mice Exhibit Lymphosplenomegaly, with Altered
Lymphocyte Subsets. One of the earliest and most impres-
sive phenotypes that is apparent in B6.Sle1|lpr mice is the
massive lymphadenopathy and splenomegaly, evident as
early as 2–3 mo of age, as illustrated in Fig. 1. At the age of
3 mo, B6.Sle1|lpr mice (n   6) have mean spleen weights
of 413 mg, which are significantly heavier than age-
matched B6 (mean   74 mg, n   8, P   0.002), B6.Sle1
(mean   90 mg, n   6, P   0.001), and B6.lpr (mean  
105 mg, n   6, P   0.006), as summarized in Table I.
Likewise, all LN in this strain are also enlarged. For in-
Figure 1. B6.Sle1|lpr mice exhibit prominent splenomegaly and lymphadenopathy, as early as 3 mo of age. (A) The enlarged cervical LNs are visible
superficially as early as 3 mo of age. (B) The cervical LNs are grossly enlarged and matted together, abutting onto the submandibular glands. Shown pic-
tures are representative of at least 12 B6.Sle1|lpr mice, at the age of 3 mo. (C) In addition to the cervical LNs, the spleen and inguinal LNs are also en-
larged (see Table I for quantitation and statistical analysis). The histology of these enlarged organs are depicted in Fig. 8.284 Sle1 and FAS Impact Alternate Pathways to Lymphoproliferative Lupus
stance, B6.Sle1|lpr inguinal LNs are  10-fold larger than
the LNs from age-matched controls (Table I).
Evidently, the increased size of the secondary lymphoid
organs is partly due to the increased cell numbers, and
partly due to the increased size of individual lymphocytes.
In particular, B6.Sle1|lpr spleens exhibit significantly
higher numbers of CD4 , and CD4 CD8  DN, but not
CD8 , T cells. On the average, each B6.Sle1|lpr spleen
Table I. FACS® Analysis of 3-mo-old (mean   SEM)
B6 B6.Sle1 B6.lpr B6.Sle1.lpr P valuea
n   8 n   6 n   6 n   6 B6 B6.Sle1 B6.lpr
Spleen Weight (mg) 74.2   10.6 89.6   5.6 105.0   9.3 413.2   97.2 ** *** **
Cell number (  10 6) 83.1   13.7 107.2   10.1 127.2   29.1 224.6   21.8 *** *** *
% CD4 T cell 15.4   1.0 15.1   0.8 16.7   1.1 27.5   0.6 *** *** ***
% CD8 T cell 10.2   0.7 10.9   0.5 9.6   1.9 6.6   0.6 ** *NS
% CD3 CD4 CD8  (DN) 4.8   1.1 8.2   1.2 15.1   2.2 15.9   2.1 *** * NS
CD4 T cell: size (mean FSC) 46.1   0.8 45.2   0.9 50.2   1.1 50.6   1.0 ** ** NS
% CD69  27.1   1.3 27.8   0.6 35.1   1.2 52.5   4.6 *** ** *
% CD25  25.4   2.8 28.2   0.3 24.6   2.0 42.4   6.9 * NS NS
% CD62L ve 51.9   3.7 44.0   3.8 72.2   3.4 79.0   0.7 ** ** NS
% CD45RB ve 31.8   4.3 38.2   3.3 50.5   3.6 81.4   1.1 *** *** **
CD8 T cell: % CD69  18.8   2.6 18.6   1.6 17.2   0.5 47.5   5.2 *** ** **
% CD25  12.1   2.0 14.8   2.1 15.1   3.9 37.0   7.2 ** * NS
% CD62L ve 52.4   3.7 34.9   4.5 65.6   3.5 84.9   2.7 *** *** *
% CD45RB ve 10.6   1.9 7.1   0.3 20.7   7.4 38.9   6.4 ** *** NS
% B1a cells 4.9   0.8 10.0   4.7 19.9   3.8 23.7   4.0 *** *** *
% B2 cells 53.8   3.3 52.1   2.2 33.6   6.8 16.8   3.4 *** *** ***
B cell: size (mean FSC) 46.2   0.8 48.2   0.8 49.1   0.7 51.5   0.7 ** * NS
I-Ab (MFI)b 1,000 1,154   55 1,163   53 2,735   125 *** *** ***
B7-1 (MFI)b 50 53.6   9.4 57.7   4.3 78.2   3.9 ** *
B7-2 (MFI)b 50 59.8   5.3 74.3   14.6 93.0   12.5 ** * NS
CD44 (MFI)b 300 303.3   9.5 360.9   32.6 570.9   61.9 *** ** *
LNc Weight (mg) 7.5   1.1 13.6   2.0 14.6   2.8 111.0   47.1  ** * * *
Cell number (  106) 2.7   0.4 4.3   1.5 4.7   1.2 17.3   3.1 ** ** **
% CD4 T cell 24.1   2.2 22.5   2.3 18.7   2.2 17.7   1.7 *** NS NS
% CD8 T cell 21.4   2.0 23.4   2.9 15.2   2.2 8.7   1.3 *** ** *
% CD3 CD4 CD8  (DN) 10.9   2.9 8.6   1.4 13.4   1.7 27.5   3.2 ** *** *
CD4 T cell (mean FSC) 46.7   1.7 45.4   2.0 48.2   1.4 52.4   0.8 ** *
CD4 T cell: % CD69  23.8   2.2 21.3   1.2 35.0   5.0 43.0   2.9 *** *** NS
CD8 T cell: % CD69  15.2   3.6 8.0   1.1 23.3   9.2 29.2   2.9 * *** NS
% B1a cells 4.5   0.4 4.7   0.8 15.5   5.1 35.1   4.8 *** *** *
% B2 cells 34.4   4.0 31.0   2.2 37.0   7.8 15.1   3.2 ** ** NS
B cell size (mean FSC) 44.7   1.7 45.5   1.3 48.1   1.3 53.5   0.6 *** ** *
PerC % B1a cells 37.6   1.7 34.5   3.4 38.1   6.1 61.1   4.8 *** *** *
% B2 cells 61.7   0.8 56.4   1.3 55.6   5.3 22.3   0.9 *** *** **
Cellular composition of B6.Sle1|lpr and control spleens, LNs, and PerC. Six to eight mice of each strain were examined at 3 mo of age. Shown values
represent mean   SEM. For the spleen and LNs, the shown percentages of CD4, CD8, DN, B1a, and B2 cells represent percentages of all
lymphocytes, whereas the percentages of B1a and B2 cells in the PerC represent percentages of all PerC B cells.
aStudent’s t test was performed to compare all three control strains with B6.Sle1|lpr mice. For the comparison of LN weights, Mann-Whitney Rank
Sum test was employed, as these data sets failed normality tests. *P   0.05; **P   0.01; and ***P   0.001. NS, not significant (P   0.05).
bEach FACS® staining experiment was conducted with B6 controls and the experimental strains in parallel. Within each experiment, the level of ex-
pression of I-Ab, B7-1, B7-2, and CD44 on B6 B cells was arbitrarily set at 1,000, 50, 50, and 300 MFI units, respectively, by adjusting the fluores-
cence channel voltage. This facilitated the comparison of staining experiments done on different days. MFI, mean fluorescence intensity.
cShown data was obtained from individual inguinal LNs isolated from the different strains.285 Shi et al.
bears 61.3   6.3   106 CD4 T cells (n   6, aged 3 mo),
compared with age-matched B6 (14.1   2.5   106, P  
10 5), B6.Sle1 (16.1   0.5   106, P   0.0002), and B6.lpr
(21.2   2.2   106, P   0.02) spleens, as can be deduced
from Table I. Since the absolute numbers of CD8 T cells
are not significantly changed, B6.Sle1|lpr spleens also ex-
hibit increased CD4:CD8 ratios (mean of six 3-mo-old
mice is 4.17), compared with age-matched B6 (mean  
1.5, n   8, P   10 6), B6.Sle1 (mean   1.4, n   6, P  
10 5), B6.lpr (mean   1.7, n   6, P   0.01), as can be de-
duced from Table I. In addition, significantly more
B6.Sle1|lpr T cells exhibit an activated/memory pheno-
type, as gauged by the surface levels of CD69, CD25,
CD62L, and CD45RB, compared with all three control
strains. Nearly twice as many 3-mo-old B6.Sle1|lpr splenic
CD4 T cells bear CD69, compared with the control strains,
with a similar trend being noted for CD25. Also,  80% of
3-mo-old B6.Sle1|lpr CD4  T cells phenotype as CD62L ve
and CD45RBlo, and a similar pattern is seen with
B6.Sle1|lpr CD8  T cells (Table I). Thus, compared with
the control strains, B6.Sle1|lpr T cells have undergone a
massive shift to an activated/memory phenotype.
The FASlpr defect is well known to expand the numbers
of DN T cells, which are CD3 ve, but negative for CD4
and CD8. These represent CD8 T cells that have failed to
undergo activation induced T cell death, and have subse-
quently downregulated their surface CD8 (23, 24). As re-
ported by others, B6.lpr spleens bear significantly higher
levels of DN T cells ( 40% of all T cells), compared with
B6 and B6.Sle1 mice (Table I). This unusual subset of T
cells is further expanded in B6.Sle1|lpr spleens (54.1   7.8  
106 cells per spleen, n   6), this being significantly higher
than the corresponding numbers in B6 (11.3   3.2  
106 DN T cells per spleen, P   0.0008) and B6.Sle1
mice (16.3   3.5   106 DN T cells per spleen, P   0.008).
Although the numbers of DN T cells in B6.Sle1|lpr
spleens are  2–3-fold higher than the corresponding
numbers in B6.lpr (17.9   6.5   106), these do not reach
statistical significance, owing perhaps to the large varia-
tions from mouse to mouse, within both strains. Fig. 2
illustrates the expansion of these T cell subsets in
B6.Sle1|lpr mice.
B6.Sle1|lpr spleens also show significant changes in the B
cell compartment. 3-mo-old B6.Sle1|lpr spleens have an
average of 41.4   7.0   106 B2 cells each. This is not sig-
nificantly different from the absolute numbers of B2 cells in
B6, B6.Sle1, and B6.lpr spleens, as can be deduced from
Table I. However, B6.Sle1|lpr spleens exhibit significantly
elevated numbers of B1 cells, mostly B1a cells, expressing
CD5. Thus, the absolute numbers of B1a cells in 3-mo-old
B6.Sle|lpr spleens (62.8   9.8    106) are significantly
higher than in the spleens of B6 (5.6   1.9   106, P  
0.0001), B6.Sle1 (11.1   5.1   106, P   0.003), and B6.lpr
(21.1   5.1   106, P   0.02). Fig. 2 illustrates the expan-
sion of B1a cells in B6.Sle1|lpr mice. All strains exhibited
minimal levels of B1b cells. B6.Sle1|lpr B2 cells also exhibit
several features of being already activated in vivo, as dem-
onstrated by their significantly increased size, and height-
ened (about twofold) surface levels of I-Ab, CD80, CD86,
and CD44, compared with the control strains (Table I).
Within the data sets examined, both male and female mice
appear to be affected equally, with respect to all of the T
and B cell phenotypes detailed in Table I.
Similar patterns are also seen in the LNs. B6.Sle1|lpr in-
guinal LNs are  10-fold larger, and fourfold more hyper-
cellular than the control LNs (Table I). In particular, DN T
cells comprise nearly half the lymphocytes in B6.Sle1|lpr
LNs. Generalized lymphocyte activation, increased CD4:CD8
ratios, and B1a cell expansion are also seen in B6.Sle1|lpr
LNs (Table I). In the PerC, the combined action of
Sle1 and FASlpr leads to a significant expansion of B1a cells,
accounting for nearly two-thirds of all the B cells at this site
(Table I). Of note, B1b (B220int, CD23lo, CD5 ve) cells
are not prominently expanded in any of the secondary
lymphoid organs of the study strains. Finally, similar
changes are also noted in the peripheral blood of these mice
Figure 2. Expansion of unusual subsets of
B and T cells in B6.Sle1|lpr spleens. Spleno-
cytes from 3-mo-old B6, B6.Sle1, B6.lpr,
and B6.Sle1|lpr mice were subjected to FACS®
analysis as described in Materials and Meth-
ods. CD4 versus CD8 plots, gated on live
CD3 ve cells (top) and B220 versus CD5
plots, gated on all live cells (bottom) are de-
picted. Shown also are the percentages of
CD3 ve cells that were CD4  (bottom
right), CD8  (top left), or “DN” (bottom
left), and the percentages of all live cells that
phenotyped as B1a (B220 , CD5 ve) or B2
(B220hi, CD5 ve, CD23 ). Shown plots
are representative of at least six mice from
each strain, as detailed and statistically ana-
lyzed in Table I.286 Sle1 and FAS Impact Alternate Pathways to Lymphoproliferative Lupus
(unpublished data). As expected, age tends to accentuate
these phenotypes. Thus, 6-mo-old B6.Sle1|lpr spleens are
twice as large (546.8   37.7 mg versus 286   32.5 mg,
n   6, P   0.002), compared with 3-mo-old B6.Sle1|lpr
spleens. The activation status of B and T cells also exhibit
similar trends of accentuation. However, it should be
pointed out that the 6-mo data are likely to be “underesti-
mates,” as  80% of B6.Sle|lpr mice are already dead by this
age (see below).
B2 Cells, but not B1a Cells, Are the Dominant Producers of
IgG ANAs. Given the prominent changes in the B cell
compartment of B6.Sle1|lpr mice (B1a expansion, and acti-
vated B2 cells), we next examined if these B cells might be
functionally important for disease. Since both the B6.Sle1
and B6.lpr strains are known to have different spectrum of
ANAs, we asked if the B6.Sle1|lpr splenic B cells secreted
any ANAs. As diagramed in Fig. 3, A and B, 3-mo-old
B6.Sle1|lpr splenic B cells secrete more IgG anti-ssDNA
(P   0.0004, P   0.022, and P   0.005, respectively), IgG
anti-dsDNA (P   0.008, P   0.036, and P   0.008, re-
spectively), IgG anti-histone/DNA (P   0.032, P   0.036,
and P   0.032, respectively), and IgG anti-histone ANAs
(P   0.008, P   0.036, and P   0.008, respectively), com-
pared with age-matched B6, B6.Sle1, and B6.lpr splenic B
cells. Importantly, these differences become very much
more pronounced with age. Thus, 6-mo-old B6.Sle1|lpr
splenic B cells secrete 40–700-fold higher levels of IgG
ANAs, compared with splenic B cells from age-matched
control mice (P   0.001). Given the observation that
B6.Sle1|lpr spleens have increased numbers B1a cells, and
activated B2, we next investigated which of these two pop-
ulations were actually producing the ANAs. To determine
this, B2 and B1a cells were FACS®-sorted from 3-mo-old
B6.Sle1|lpr spleens, and cultured in vitro for 5 d, with LPS.
As depicted in Fig. 3 C, IgG ANAs arise predominantly
from splenic B2 cells, rather than B1a cells.
B6.Sle1|lpr Mice Exhibit a Wide Spectrum of Serum Au-
toantibodies. As one might have extrapolated from the
above findings, the epistatic interaction of Sle1 with FASlpr/lpr
also leads to high titres of serum IgM and IgG autoanti-
bodies, as early as 3 mo of age (Fig. 4). This includes anti-
nuclear specificities, as well as Abs that acquire affinity for
glomerular antigens. Compared with 3-mo-old B6 mice,
B6.Sle1 mice exhibit  1.5–2-fold higher levels of total IgG
(P   0.009); however, this monocongenic strain does not
exhibit high levels of ANAs at this early age, but only
when much older (7). Compared with 3-mo-old B6 mice,
B6.lpr sera exhibit 1–3-fold higher levels of total IgG (P  
0.02), IgG anti-histone (P   0.001), IgG anti-ssDNA (P  
0.001), and several specificities of IgM ANAs. B6.Sle1|lpr
mice, as early as 3 mo of age, exhibit significantly elevated
total serum IgM and IgG (P   0.001), and an impressive
array of IgG and IgM ANAs, targeting ssDNA, dsDNA,
histone/DNA, and histones. In addition to ANAs, it is
clear from Fig. 4, that B6.Sle1|lpr mice also develop signif-
icantly (100–1,000-fold) higher levels of IgM and IgG anti-
glomerular Abs (P   0.001, compared with the control
strains). As noted for the cellular phenotypes, age accentu-
ates the ANA serotitres, but the observed levels are likely
to be “underestimates,” as  80% of B6.Sle|lpr mice are
dead by this age (see below). It is interesting to note that
3-mo-old female B6.Sle1|lpr mice have significantly higher
IgG autoantibody levels to dsDNA (P   0.024), and his-
tone/DNA (P   0.026), and IgM autoantibodies to ds-
DNA (P   0.002), and ssDNA (P   0.008), compared
with their male counterparts (unpublished data). Indeed,
this is the only phenotype where we could demonstrate
any statistically significant sex differences.
Sle1 Exerts a Gene-Dosage Effect. To ascertain the ne-
cessity for homozygosity at either of the two loci studied
(Sle1,  FASlpr), mice that are heterozygous at these loci
were also examined. As depicted in Fig. 5, B6.Sle1 / |lpr
Figure 3. In vitro IgG ANA production of by B6.Sle1|lpr splenic B
cells. Total splenocytes from 3-mo-old (A) and 6-mo-old (B) mice were
cultured (106 cells per well) for 5 d with LPS. For each strain, splenocytes
from 3–6 individual mice were cultured. Shown values represent mean
(  SEM) levels of ANAs secreted by the 3–6 independent cultures from
each strain. B6.Sle1|lpr splenocytes produce significantly more IgG
ANAs, compared with the control strains, both at the 3-mo age (P  
0.036), and at the 6-mo age (P   0.001), as detailed in the text. (C)
B220int, CD23lo, CD5 ve (B1a) and B220hi, CD23hi, CD5 ve (B2) cells
were FACS® sorted from B6.Sle1|lpr spleens, and cultured (106 cells per
well), for 5 d, with LPS. The culture supernatants were assayed for IgG
anti-dsDNA and anti-histone/DNA levels, by ELISA. Shown ELISA
ODs represent three independent FACS® sorting experiments. Within
each experiment, the ANA levels produced by B1a cells and B2 cells from
the same B6.Sle1|lpr spleen are shown connected by lines.287 Shi et al.
mice have significantly larger spleens (P   0.025), in-
creased CD69  CD4 T cells (P   0.01), and elevated se-
rum IgG anti-ssDNA and anti-histone/DNA ANAs (P  
0.02), compared with B6.lpr mice, as early as 3 mo of age.
However, most of their phenotypes are less dramatic than
those seen in B6.Sle1|lpr mice. Thus, the B6.Sle1 / |lpr
spleens weights (P   0.02), CD4:CD8 ratios (P   0.004),
mean B cell size (P   0.002), B1a cell expansion (P  
0.025), and IgG anti-dsDNA levels (P   0.05), are all sig-
nificantly less than that seen in B6.Sle1|lpr mice (Fig. 5).
Thus, in the absence of FAS function (lpr/lpr genotype),
Sle1 appears to exert a gene dosage effect. In contrast,
B6.Sle1|lpr /  mice do not differ significantly from
B6.Sle1 mice, phenotypically. Thus, in the context of the
Sle1/Sle1 genotype, having a single allele of FAS negated
does not significantly accentuate any of the Sle1-triggered
phenotypes (Fig. 5).
B6.Sle1|lpr Mice Exhibit Severe Clinical and Histological
GN. Since the B6.Sle1|lpr mice exhibit high titres of
potentially pathogenic ANAs, it is important to evaluate
the extent of renal pathology and disease in this strain. As
depicted in Fig. 6 A, B6.Sle1|lpr mice exhibit significantly
higher levels of urinary protein, compared with B6 (P  
0.0003), and B6.lpr mice (P   0.02), as early as 3 mo of
age. At this age, B6.Sle1|lpr mice also exhibit significantly
higher levels of BUN (Fig. 6 B), compared with B6 (P  
0.001), B6.Sle1 (P   0.025), and B6.lpr (P   0.024).
Both, male and female B6.Sle1|lpr mice show equally high
24-h urinary protein (P   0.37) and BUN (P   0.24). In-
terestingly, there was also a fairly good correlation be-
tween IgG anti-dsDNA levels and 24-h urinary protein
(n   12 mice, aged 6 mo, correlation coefficient   0.86).
As one would predict, B6.Sle1|lpr kidneys demonstrate sev-
eral features of chronic GN, which become more pro-
nounced with age. These include Grade 4 proliferative
glomerulopathy (noted in four out of six kidney sections
examined) with hyaline mesangial deposits, evidence of
interstitial infiltrates, (as illustrated in Fig. 6 C), pertina-
cious deposits in the tubules, and glomerular Ig deposits
(unpublished data). However, no significant vasculitis or
tubular changes were seen.
B6.Sle1|lpr Mice Exhibit Accelerated Mortality, most likely
from Renal Failure. As one might have predicted from the
serology and pathology, B6.Sle1|lpr mice suffer signifi-
cantly increased mortality, as diagramed in Fig. 7. At 3 mo
of age, none of the B6, B6.Sle1, and B6.lpr mice are dead,
Figure 4. Impact of Sle1|lpr on serum Ig and ANAs. 3-mo-old B6 (n  
14), B6.Sle1 (n   14), B6.lpr (n   6), and B6.Sle1|lpr (n   19) mice were
examined for their serum levels of total IgM and IgG, as well as IgM and
IgG autoantibodies to ssDNA, dsDNA, histone/DNA, total histones, and
renal glomeruli. Sera that exhibited autoantibody levels beyond the linear
range of the assay were diluted further, and reassayed. Shown bars depict
the mean autoantibody levels in each strain. Depicted below each strain
also are the P values, compared with the autoantibody levels in
B6.Sle1|lpr mice.
Figure 5. Impact of heterozygosity at the Sle1 locus, on
autoimmune phenotypes. 3-mo-old B6.Sle1 / |lpr mice
(heterozygous at Sle1, homozygous for FASlpr, n   6–8),
and B6.Sle1|lpr /  mice (homozygous at Sle1, but het-
erozygous for FASlpr, n   6–12), are compared with age-
matched B6, B6.Sle1, B6.lpr, and B6.Sle1|lpr mice, with
respect to spleen weights (A), splenic CD4:CD8 ratios (B),
activation status of splenic CD4 T cells (C), serum IgG
anti-ssDNA (D), IgG anti-histone/DNA (E), and IgG
anti-dsDNA ANAs (F). Mean   SEM are shown. White
boxes represent wild-type (B6) alleles, whereas black boxes
represent the (NZM2410-derived) Sle1, or the mutant
FASlpr alleles. Thus, the semiopen boxes represent het-
erozygosity at the respective loci. The data pertaining to
the B6, B6.Sle1, B6.lpr, and B6.Sle1|lpr strains can be sur-
mised from Table I and Fig. 4.288 Sle1 and FAS Impact Alternate Pathways to Lymphoproliferative Lupus
whereas   14% of male B6.Sle1|lpr, and 28% of female
B6.Sle1|lpr mice are dead by this age. The cumulative
6-mo mortality rate in this strain is 70% among males, and
90% among females. Although the females tend to have
worse mortality, the observed differences are not statisti-
cally different. Although these mice have clear evidence of
clinical GN (with raised BUN, and increased proteinuria),
we wondered if additional pathology elsewhere might also
be contributing to death.
To explore this, a whole body pathological screen was
conducted in 6-mo-old B6.Sle1|lpr mice (n   5–6). As ex-
pected, B6.Sle1|lpr spleens exhibit grossly enlarged white
pulp, filled with a sea of reactive lymphocytes (Fig. 8 A).
Enlarged reactive LNs (cervical, submandibular, inguinal,
pancreatic, and Peyer’s patches) were seen in all six of the
mice examined. Typically, the medullary sinuses and lym-
phatic channels of the LNs were plugged with lympho-
cytes. Some LNs also revealed rich aggregates of plasma
cells in the marginal zones. In addition, three out of the six
cervical LNs examined revealed areas of hemorrhage (Fig.
8 B). Four out of the five lungs examined, exhibited an an-
giocentric (but not peribronchial) pattern of cellular infil-
trates, as depicted in Fig. 8 C. Five out of six livers exam-
ined, exhibited varying degrees of portal triaditis (Fig. 8 D)
and nodular hyperplasia (with disarrayed hepatocyte archi-
tecture). However, these changes appear unlikely to have
caused death in these mice. No significant pathological
changes were noted in B6.Sle1|lpr heart, skin, thymus,
pancreas, salivary gland, stomach, and intestinal sections.
Discussion
We have recently reported that the epistatic interaction
of the lupus susceptibility loci, Sle1 and Sle3 (on the B6
background), is sufficient to recreate most of the lupus phe-
notypes seen in lupus-prone NZM2410 mice, from which
strain these loci originate (10). Whereas Sle1 appears to be
critical in breaching tolerance to chromatin, Sle3 reduces
activation induced T cell death, accompanied by increased
CD4:CD8 ratios, and low titres of ANAs. Indeed, in sev-
eral respects, B6.Sle3 mice resemble B6.lpr mice, pheno-
typically (9). Thus, we reasoned that epistatic interactions
of Sle1 with FASlpr mice might also lead to phenotypes that
are similar to those seen in B6.Sle1|Sle3 mice.
As predicted, the epistatic interaction of Sle1 with
FASlpr precipitates several autoimmune features with a
Figure 6. Evidence of renal disease in B6.Sle1|lpr mice. (A) BUN and
(B) 24-h urinary protein levels were assayed in 3-mo-old B6, B6.Sle1,
B6.lpr and B6.Sle1|lpr mice. Each dot represents a single animal. The
dotted line represents 2 SD in excess of the mean levels in age-matched
B6, which was used as the cut-off to define positives. (C) Typical renal
changes included enlarged glomeruli (G) with proliferative changes affect-
ing  50% of glomeruli (Grade 4 GN), and hyaline, mesangial deposits. In
addition, two of the six kidneys studied also demonstrated interstitial infil-
trates (pointed by arrow).
Figure 7. Increased mortality in B6.Sle1|lpr mice. A cohort of 16–20
B6, B6.Sle1, B6.lpr, and B6.Sle1|lpr mice were monitored until the age of
8 mo. The three control strains do not exhibit any death until 8 mo of age
(solid line, superimposed for all three strains). The mortality curves for the
male and female B6.Sle1|lpr mice are indicated by dotted lines, as pointed
out in the figure.289 Shi et al.
very early age of onset. The extent of splenomegaly and
generalized lymphadenopathy, the degree of lymphocyte
activation, the levels of serum ANAs, and the extent of re-
nal disease are far more severe and acute in onset, com-
pared with the B6.Sle1|Sle3 bicongenic strain (10). In-
deed, in many respects, these mice resemble PTEN
haploinsufficient mice (25–27). The expansion in absolute
numbers of activated CD4  T cells and B cells is remark-
able. The increased CD4:CD8 ratios in B6.Sle1|lpr mice
are similar to those seen in the NZM2410 lupus prone
mice. However, the expansion of DN T cells is not a fea-
ture of the NZM2410 strain, or the B6.Sle congenics. It is
very likely that the DN T cells have arisen from CD8  T
cells that have failed to undergo apoptosis, as has been
demonstrated in B6.lpr mice (23, 24). The expansion of
DN T cells in B6.Sle1|lpr mice (relative to the levels seen
in B6.lpr mice) suggests that Sle1 itself is facilitating the ac-
tivation of CD8 (and CD4) T cells, that then resist AICD,
hence leading to an accumulation of these cells as DN T
cells. These observations strongly suggest that Sle1 is also
impacting the T cell compartment, in addition to the pre-
viously documented intrinsic impact on B cells (12).
B1a cells are not prominent in B6.Sle1 mice (7). It has
also been reported that this population of B cells is not
prominent in MRL.lpr mice, as well (28). However, in
our colony, B6.lpr mice themselves reveal a respectable
expansion of B1a cells, constituting  37% of all splenic
B-cells, as presented in Table I. In contrast, the epistatic
interaction of Sle1 and FASlpr leads to a massive expansion of
B1a cells, which comprise  60% of splenic B cells in these
mice (Table I). The finding that the CD5 molecule be-
comes expressed on anti-self B-cells entering an anergic
state after chronic antigenic stimulation (29), and the re-
ports that CD5 transmits inhibitory signals in B cells (30),
are consistent with the following model. The epistatic in-
teraction of Sle1 with FASlpr is sufficient to impede lym-
phocyte apoptosis strongly enough, so that activated B2
cells accumulate over time. The ongoing incessant au-
toimmune signaling then drives more and more of these B
cells to express CD5, in an “attempt” to downregulate the
autoimmune response. Consistent with this model, and
the reports from other lupus strains (31–33), most of the
IgG ANAs appear to be produced by the B2 cells, rather
than the B1a cells (Fig. 2 C). Finally, it is tempting to draw
a parallel between the DN T cells and the B1a cells, in
these mice: both are believed to represent lymphocytes
that have been chronically activated, but had resisted sub-
sequent purging. It is interesting to note that both these
unusual populations of lymphocytes are somewhat ele-
vated in B6.lpr mice, and both become significantly ex-
panded in B6.Sle1|lpr mice.
The serological and renal phenotypes in B6.Sle1|lpr
mice resemble those seen in B6.Sle1|Sle2|Sle3 (13),
NZM2410, and other lupus models, and do not appear to
be unique in any fashion. However, it’s worth stressing the
point that the epistatic interaction of Sle1 and FASlpr is suf-
ficient to engender nephrophilic, anti-dsDNA ANAs, and
grade 4 GN with increased proteinuria and BUN, all being
phenotypes not prominent in either the B6.Sle1 or B6.lpr
strain. Thus, it appears that whereas Sle1 by itself is suffi-
cient to breach the tolerance of anti-histone/DNA B-cells,
the combined defects of Sle1 and FASlpr are potent enough
Figure 8. Histopathological
changes in other B6.Sle1|lpr or-
gans. (A) Spleens, (B) LNs, (C)
lungs, and livers of 6-mo-old
B6.Sle1.lpr ( n    5–6) were
stained with H&E, and examined
for evidence of any pathological
changes. B6.Sle1|lpr spleens (A)
exhibit expansion of the white
pulp (WP), compared with the
red pulp (RP). The white pulp is
expanded by reactive lympho-
cytes. Shown section is represen-
tative of five out of six spleens
examined. Similar changes are
also seen in the enlarged cervical
LNs (B), which are also charac-
terized by areas of hemorrhage
(H). Four out of five B6.Sle1|lpr
lungs (C) demonstrate cellular
infiltrates that are curiously local-
ized in an angiocentric fashion
(AC), around blood vessels. Five
out of six B6.Sle1|lpr livers (D)
demonstrate cellular infiltrates
that showed a congregation
around the portal triads (PT),
with varying degrees of nodular
hyperplasia. Original magnifica-
tion    400.290 Sle1 and FAS Impact Alternate Pathways to Lymphoproliferative Lupus
to rescue even the nephrophilic and dsDNA-reactive B
cells from the tolerance checkpoints. These conclusions are
presently being verified using Ig Tg models of tolerance. It
is also important to note the fairly good correlation be-
tween these phenotypes: the correlation coefficient be-
tween IgG anti-dsDNA ANAs and 24-h urinary protein in
6-mo-old B6.Sle1|lpr mice was 0.86. The mortality rate in
this strain parallels that in the B6.Sle1|Sle2|Sle3 triple con-
genic mice (13), and is far quicker than in NZM2410 mice.
Given the absence of other potential causes of death (based
on the pathological survey), and the clear evidence of his-
tological and clinical nephritis, it appears most likely these
mice are dying from renal failure.
There are several literature reports of mouse strains with
lymphoproliferative autoimmunity on the normal (B6 or
B6/129) background with phenotypes close to those seen
in B6.Sle|lpr strain. B6.lpr|Bcl2Tg mice also develop massive
lymphadenopathy with increased numbers of DN T cells
(34). However, these mice do not exhibit elevated IgG
ANAs, B1 cells, GN, or early mortality. Thus, this strain is
clearly different from B6.Sle1|lpr mice, except for the mas-
sive lymphadenopathy. Perhaps the closest resemblance to
our strain is the B6/129.PTEN /  strain (25). PTEN en-
codes a phosphatase that is homozygously mutated in a
high percentage of human tumors (35, 36). Although ho-
mozygous deficiency leads to embryonic lethality, B6/
129.PTEN /  mice develop severe lymphadenopathy
prominently affecting the submandibular, axillary, and in-
guinal LNs, similar to B6.Sle1|lpr mice. These mice also
develop high titres of IgG ANAs, and die of GN with a
time course that is similar to B6.Sle1|lpr mice. Importantly,
B6/129.PTEN /  mice also exhibit an expanded B1a cell
population (25), akin to that observed in the B6.Sle1|lpr
strain. Likewise, mice that hyperexpress PI3 kinase also ex-
hibit similar phenotypes (37). Ongoing studies are aimed at
determining how FASlpr and Sle1 may be differentially im-
pacting specific apoptotic/survival pathways. Collectively,
the above reports establish that the infringement of key ap-
optotic/survival pathways has the potential to trigger lym-
phoproliferative autoimmunity (38–40).
These studies also have important implications for our
understanding of autoimmune lymphoproliferative syn-
drome (ALPS). Patients with ALPS also develop massive
lymphosplenomegaly with concomitant autoimmunity. As
extensively reviewed (41–44), most of these patients ex-
hibit mutations ion FAS/FASL. Nevertheless, family stud-
ies clearly indicate that FAS/FASL defects alone may not
be sufficient for ALPS to develop – a “second hit” appears
to be required (45, 46). Based on the findings in
B6.Sle1|lpr mice, we posit that Sle1 (and other players in
the same pathway) might constitute this “second hit.” It is
now clear that Sle1 is not only a murine lupus/ALPS sus-
ceptibility locus, the syntenic region on human chromo-
some 1 also appears to confer lupus susceptibility (47–49).
Thus, this locus on human and murine chromosome 1
potentially holds important clues for our understanding of
not only lupus, but also ALPS. Decoding Sle1 and defin-
ing the molecular pathways impacted by FAS and Sle1
will lay out the molecular blueprints for lymphoprolifera-
tive lupus.
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